An overview of immune checkpoint inhibitors in breast cancer
Federica Miglietta(University of Padua), Nicla La Verde(ASST Fatebenefratelli Sacco), Maria Silvia Cona(Luigi Sacco Hospital), Valentina Guarneri(Istituto Oncologico Veneto), Maria Vittoria Dieci(Istituto Oncologico Veneto)
Cited by 7
Related Papers
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer
|Journal of Clinical Oncology|2007|290
Evolution of HER2-low expression from primary to recurrent breast cancer
|npj Breast Cancer|2021|226